Advertisement
Screener

Filana Therapeutics, Inc. (FLNA) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

FILANA THERAPEUTICS, INC. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • FILANA THERAPEUTICS, INC. return tang equity for the quarter ending 2026-03-31 was -114.65%, a change of -57.59% year-over-year.
  • FILANA THERAPEUTICS, INC. return tang equity for the quarter ending 2025-12-31 was -122.59%, a change of -105.88% year-over-year.
  • FILANA THERAPEUTICS, INC. return tang equity for the quarter ending 2025-09-30 was -130.05%, a change of -119.45% year-over-year.
  • FILANA THERAPEUTICS, INC. return tang equity for the quarter ending 2025-06-30 was -140.06%, a change of -131.93% year-over-year.
  • FILANA THERAPEUTICS, INC. return tang equity for fiscal 2025 was -122.59%, a change of -105.88% from fiscal 2024.
  • FILANA THERAPEUTICS, INC. return tang equity for fiscal 2024 was -16.71%, a change of 54.10% from fiscal 2023.
  • FILANA THERAPEUTICS, INC. return tang equity for fiscal 2023 was -70.81%, a change of -37.21% from fiscal 2022.
  • FILANA THERAPEUTICS, INC. return tang equity for fiscal 2022 was -33.60%, a change of -20.79% from fiscal 2021.
Available history
2009-12-31 to 2026-03-31
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-03-31-114.65%-$77.9M$67.95M
2025-12-31-122.59%-$90.97M$74.21M
2025-09-30-130.05%-$106.03M$81.53M
2025-06-30-140.06%-$123.17M$87.94M
2025-03-31-57.05%-$72.79M$127.58M
2024-12-31-16.71%-$24.34M$145.67M
2024-09-30-10.60%-$17.66M$166.57M
2024-06-30-8.14%-$15.37M$188.89M
2024-03-31-61.04%-$47.9M$78.48M
2023-12-31-70.81%-$97.22M$137.29M
2023-09-30-61.63%-$95.43M$154.85M
2023-06-30-50.31%-$90.04M$178.97M
2023-03-31-40.78%-$82.99M$203.5M
2022-12-31-33.60%-$76.25M$226.92M
2022-09-30-35.98%-$71.28M$198.1M
2022-06-30-27.86%-$60.59M$217.51M
2022-03-31-19.64%-$46.39M$236.15M
2021-12-31-12.81%-$32.39M$252.84M
2021-09-30-7.81%-$20.83M$266.63M
2021-06-30-4.61%-$12.7M$275.41M
2021-03-31-3.11%-$8.71M$280.11M
2020-12-31-6.95%-$6.33M$91.13M
2020-09-30-21.82%-$5.23M$23.97M
2020-06-30-18.60%-$4.5M$24.18M
2020-03-31-17.81%-$4.42M$24.83M
2019-12-31-20.96%-$4.63M$22.1M
2019-09-30-21.74%-$3.79M$17.45M
2019-06-30-24.47%-$4.36M$17.82M
2019-03-31-31.02%-$5.76M$18.55M
2018-12-31-33.40%-$6.56M$19.63M
2018-09-30-41.54%-$8.3M$19.97M
2018-06-30-112.57%-$9.62M$8.55M
2018-03-31-109.98%-$11.33M$10.3M
2017-12-31-122.81%-$11.91M$9.7M
2017-09-30-105.70%-$12.02M$11.37M
2017-06-30-97.54%-$12.94M$13.27M
2017-03-31-70.56%-$11.8M$16.72M
2016-12-31-79.68%-$14.85M$18.64M
2016-09-30-82.92%-$16.85M$20.32M
2016-06-30-73.95%-$17M$22.99M
2016-03-31-68.65%-$17.36M$25.28M
2015-12-31-48.17%-$14.15M$29.37M
2015-09-30-35.64%-$11.78M$33.07M
2015-06-30-32.40%-$11.65M$35.94M
2015-03-31-29.97%-$11.52M$38.44M
2014-12-31-30.92%-$12.39M$40.06M
2014-09-3055.29%$22.79M$41.21M
2014-06-3058.55%$25.56M$43.65M
2014-03-3162.37%$28.5M$45.7M
2013-12-3165.31%$31.54M$48.3M
2013-09-30-22.91%-$3.27M$14.25M
2013-06-30-28.59%-$4.05M$14.18M
2013-03-31-28.95%-$3.88M$13.41M
2012-12-31-26.22%-$3.44M$13.14M
2012-09-30-4.41%-$2.04M$46.33M
2012-06-30-2.83%-$1.31M$46.17M
2012-03-31-5.25%-$2.38M$45.3M
2011-12-31-5.89%-$2.61M$44.39M
2011-09-30-26.20%-$11.39M$43.49M
2011-06-30-26.97%-$11.61M$43.03M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-122.59%-$90.97M$74.21M
2024-12-31-16.71%-$24.34M$145.67M
2023-12-31-70.81%-$97.22M$137.29M
2022-12-31-33.60%-$76.25M$226.92M
2021-12-31-12.81%-$32.39M$252.84M
2020-12-31-6.87%-$6.33M$92.2M
2019-12-31-20.96%-$4.63M$22.1M
2018-12-31-33.41%-$6.56M$19.63M
2017-12-31-122.81%-$11.91M$9.7M
2016-12-31-79.68%-$14.85M$18.64M
2015-12-31-48.17%-$14.15M$29.37M
2014-12-31-30.92%-$12.39M$40.06M
2013-12-3165.31%$31.54M$48.3M
2012-12-31-26.23%-$3.45M$13.14M
2011-12-31-5.89%-$2.61M$44.39M
2010-12-31-36.51%-$12.02M$32.93M
2009-12-31-3.20%-$3.47M$108.25M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
PMGC Holdings Inc. (ELAB)United States$0.037B
Celularity Inc (CELU)United States$0.038B-0.34
BriaCell Therapeutics Corp. (BCTX)$0.037B
CervoMed Inc. (CRVO)United States$0.038B-1.39
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Incannex Healthcare Inc. (IXHL)$0.040B-22.32